Charts for most psychedelic drug stocks look terrible in recent weeks. The same was true in the summer of 2020 -- immediately before these stocks exploded higher. Deja vu?

In the past week, of the 41 psychedelic drug stocks that trade on the various North American stock exchanges only nine went up in price, while 31 went down and one had no change.

Two pandemics are currently afflicting the planet. While our governments focus on the smaller one (COVID-19), the larger one (the Mental Health Crisis) is rapidly spiralling out of control.

The COVID pandemic is (indirectly) making the psychedelic drug industry a much more attractive investment opportunity. The catch? It's also drowning out coverage of this emerging sector.

The January performances of the 37 stocks within the fledgling but burgeoning psychedelic bio-pharmaceutical drug stocks sector.